
Roche has unveiled new Phase 3 data for its haemophilia A treatment Helimbra (emicizumab) in patients over 12 years of …

The FDA has announced the approval of Mylan’s Ogivri (trastuzumab-dkst), the first biosimilar version of Roche’s Herceptin to be authorised …

Roche has unveiled new Phase 3 efficacy data which showed strong findings for its immunotherapy Tecentriq (atezolizumab) in combination with …

Samsung Bioepis has announced that Ontruzant, the company’s biosimilar version of Roche’s Herceptin, has been awarded marketing authorisation in Europe …

Roche needs its pipeline to pick up quick successes, with its big earners are looking at precipitous patent cliffs, and, …

Genentech first signed a deal with Arvinas, a biotech focused on drugs within the protein degradation class, back in 2015. …

Roche has revealed that its humanised monoclonal antibody Ocrevus (ocrelizumab) received a positive recommendation from the Committee for Medical Products …

NHS England has entered into a commercial agreement with Merck which aims to provide access to innovative treatments for both …

The FDA has announced the approval of Roche’s Zelboraf (vemurafenib) in the treatment of Erdheim-Chester Disease (ECD), expanding its already …

In a rare spot of good news for Tecentriq (atezolizumab), after a turbulent period, Roche’s drug has been given the …

New findings of a report by PwC have revealed the biggest spenders in R&D worldwide as global spending hits $700 …

Roche had tentatively begun to re-enter the antibiotic space, but it has now signalled its growing intention to move in …

NICE has announced it has published its final draft guidance for two cancer treatments, covering Bayer’s Stivarga (regorafenib) in the …

Roche has revealed that the FDA has given approval to its cobas Zika test to determine whether a blood sample …

South Africa’s Competition Commission has admitted that there is no case to be heard against Aspen and Equity, in regards …